Pharmacogenetics of Statin-Induced Myotoxicity

Frontiers in Genetics

Paul Ken Leong Chin¹  Martin A. Kennedy²  Simran D. S. Maggo²  Ping Siu Kee² 

[1] Department of Medicine, University of Otago, Christchurch, New Zealand;Gene Structure and Function Laboratory, Carney Centre for Pharmacogenomics, Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand;

关键词: statins;    pharmacogenetics;    pharmacogenomics;    muscle toxicity;    myotoxicity;    adverse effects;   

DOI  :  10.3389/fgene.2020.575678

来源: DOAJ

【 摘 要 】

Statins, a class of lipid-lowering medications, have been a keystone treatment in cardiovascular health. However, adverse effects associated with statin use impact patient adherence, leading to statin discontinuation. Statin-induced myotoxicity (SIM) is one of the most common adverse effects, prevalent across all ages, genders, and ethnicities. Although certain demographic cohorts carry a higher risk, the impaired quality of life attributed to SIM is significant. The pathogenesis of SIM remains to be fully elucidated, but it is clear that SIM is multifactorial. These factors include drug–drug interactions, renal or liver dysfunction, and genetics. Genetic-inferred risk for SIM was first reported by a landmark genome-wide association study, which reported a higher risk of SIM with a polymorphism in the SLCO1B1 gene. Since then, research associating genetic factors with SIM has expanded widely and has become one of the foci in the field of pharmacogenomics. This review provides an update on the genetic risk factors associated with SIM.

【 授权许可】

Unknown